Article
A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2.
Cancer research and treatment - 1 Apr 2019
Park Cheol-Kyu, Cho Hyun-Ju, Choi Yoo-Duk, Oh In-Jae, Kim Young-Chul
Abstract excerpt
PURPOSE: Administering the best treatment after failure of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy requires knowledge of resistance status. In this trial, treatment efficacy of osimertinib was assessed in patients with non-small cell lung carcinoma (NSCLC) harboring the T790M resistance mutation, detected from circulating tumor DNA (ctDNA) with unknown tumor mutation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.